Tom Li

Image
Tom Li

Tom Li, PhD

Title
Associate Professor
Unit / Department / Division
Medicinal Chemistry and Pharmacognosy
Email Address
Phone Number

Professional Interests

Professional Interests

The research area of Dr. Li focuses in the design, synthesis and biochemical testing of steroidal and non-steroidal steroid sulfatase inhibitors as potential agents for the treatment of hormone-dependent cancers. Estrogen levels in breast tumors of post-menopausal women are as much as 10 times higher than estrogen levels in plasma, presumably due to in situ formation of estrogen. The major source of estrogen in breast cancer cells may be conversion of estrone sulfate to estrone by the enzyme estrone sulfatase. One of their goals is to develop potent estrone sulfatase inhibitors as potential agents for the treatment of estrogen-dependent breast cancer. They have synthesized both the steroidal and non-steroidal estrone sulfatase inhibitors.

Education

  • 1988, PhD, The Ohio State University, Medicinal Chemistry
  • 1983, BS, University of Wyoming, Pharmacy
  • 1980, Please enter degree name, University of Nevada, Pre-Pharmacy

Honors

  • School of Pharmacy Award for Excellence in Scholarship, 1997
  • President's Award for Excellence, 1997
  • Distinguished Presentation of the 14th annual meeting, Graduate Student Forum, 1988
  • University Graduate Associate Teaching Award, 1987
  • University Fellowship, 1983 - 1984

Journal Articles

Kong X, Xing E, Zhuang T, Li PK, Cheng X. Mechanistic Insights into the Allosteric Inhibition of Androgen Receptors by Binding Function 3 Antagonists from an Integrated Molecular Modeling Study. J Chem Inf Model. 2021 Jul 26;61(7):3477-3494. doi: 10.1021/acs.jcim.1c00124. Epub 2021 Jun 24. PMID: 34165949.

Liu C, Armstrong CM, Ning S, Yang JC, Lou W, Lombard AP, Zhao J, Wu CY, Yu A, Evans CP, Tepper CG, Li PK, Gao AC. ARVib suppresses growth of advanced prostate cancer via inhibition of androgen receptor signaling. Oncogene. 2021 Jul 16. doi: 10.1038/s41388-021-01914-2. Epub ahead of print. PMID: 34272475.

Larue RC, Xing E, Kenney AD, Zhang Y, Tuazon JA, Li J, Yount JS, Li PK, Sharma A. Rationally Designed ACE2-Derived Peptides Inhibit SARS-CoV-2. Bioconjug Chem. 2021 Jan 20;32(1):215-223. doi: 10.1021/acs.bioconjchem.0c00664. Epub 2020 Dec 24. PMID: 33356169; PMCID: PMC7784661.

Armstrong CM, Liu C, Liu L, Yang JC, Lou W, Zhao R, Ning S, Lombard AP, Zhao J, D'Abronzo LS, Evans CP, Li PK, Gao AC. Steroid Sulfatase Stimulates Intracrine Androgen Synthesis and is a Therapeutic Target for Advanced Prostate Cancer. Clin Cancer Res. 2020 Nov 15;26(22):6064-6074. doi: 10.1158/1078-0432.CCR-20-1682. Epub 2020 Sep 14. PMID: 32928794; PMCID: PMC7669645.

Wu S, Chan C, Zhuang T, Li PK, Cheng X. A computational study of effects on membrane recruitment of the polar linkers in Vitamin E derivatives. Biochim Biophys Acta Gen Subj. 2020 Oct;1864(10):129655. doi: 10.1016/j.bbagen.2020.129655. Epub 2020 Jun 11. PMID: 32535151.

Wang B, Li PK, Ma JX, Chen D. Therapeutic Effects of a Novel Phenylphthalimide Analog for Corneal Neovascularization and Retinal Vascular Leakage. Invest Ophthalmol Vis Sci. 2018 Jul 2;59(8):3630-3642. doi: 10.1167/iovs.18-24015. PMID: 30029250; PMCID: PMC6054429.

Arend RC, Londoño-Joshi AI, Gangrade A, Katre AA, Kurpad C, Li Y, Samant RS, Li PK, Landen CN, Yang ES, Hidalgo B, Alvarez RD, Straughn JM, Forero A, Buchsbaum DJ. Correction: Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer. Oncotarget. 2018 Apr 10;9(27):19459. doi: 10.18632/oncotarget.25151. Erratum for: Oncotarget. 2016 Dec 27;7(52):86803-86815. PMID: 29721216; PMCID: PMC5922410.

Tang Z, Acuña UM, Fernandes NF, Chettiar S, Li PK, DE Blanco EC. Structure- Activity Relationship of Niclosamide Derivatives. Anticancer Res. 2017 Jun;37(6):2839-2843. doi: 10.21873/anticanres.11635. PMID: 28551619.

Sugimoto Y, Sawant DB, Fisk HA, Mao L, Li C, Chettiar S, Li PK, Darby MV, Brueggemeier RW. Novel pyrrolopyrimidines as Mps1/TTK kinase inhibitors for breast cancer. Bioorg Med Chem. 2017 Apr 1;25(7):2156-2166. doi: 10.1016/j.bmc.2017.02.030. Epub 2017 Feb 16. PMID: 28259529.

Arend RC, Londoño-Joshi AI, Gangrade A, Katre AA, Kurpad C, Li Y, Samant RS, Li PK, Landen CN, Yang ES, Hidalgo B, Alvarez RD, Straughn JM, Forero A, Buchsbaum DJ. Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer. Oncotarget. 2016 Dec 27;7(52):86803-86815. doi: 10.18632/oncotarget.13466. Erratum in: Oncotarget. 2018 Apr 10;9(27):19459. PMID: 27888804; PMCID: PMC5349955.